Share price is starting to recover from the initial shock of smaller than anticipated revenue last quarter. We now know that the main reason for this is the extended trial periods. But the market isn't that smart when it comes to the finer details.
The other point I'd make is that any revenue at this stage shows that the billing system/software is working. That in itself wouldn't be that easy to set up. (My guess). There will be different types of billing arrangements now and in the future. Positive is that SYT is on top of it early on. Trial period(s) end, and revenue flows in.
SYT - Emails & Research, page-160
-
- There are more pages in this discussion • 1,826 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)